Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02401542
Title	Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (FIERCE-21)
Acronym	FIERCE-21
Recruitment	Terminated
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Rainier Therapeutics
Indications	ureter transitional cell carcinoma bladder urothelial carcinoma renal pelvis transitional cell carcinoma urethra transitional cell carcinoma
Therapies	Docetaxel + Vofatamab Vofatamab Docetaxel
Age Groups:	adult \| senior
Covered Countries	USA \| ITA \| GBR \| ESP